The duration of protection against clinical malaria provided by the combination of seasonal RTS,S/AS01
Malaria
Malaria vaccination
Plasmodium falciparum
RTS,S/AS01E
Seasonal malaria chemoprevention
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
07 10 2022
07 10 2022
Historique:
received:
26
04
2022
accepted:
18
08
2022
entrez:
6
10
2022
pubmed:
7
10
2022
medline:
12
10
2022
Statut:
epublish
Résumé
A recent trial of 5920 children in Burkina Faso and Mali showed that the combination of seasonal vaccination with the RTS,S/AS01 In order to help optimise the timing of these two interventions, trial data were reanalysed to estimate the duration of protection against clinical malaria provided by RTS,S/AS01 The overall protective efficacy from RTS,S/AS01 The efficacy of both interventions was highest immediately post-administration. Understanding differences between these interventions in their peak efficacy and how rapidly efficacy declines over time will help to optimise the scheduling of SMC, malaria vaccination and the combination in areas of seasonal transmission with differing epidemiology, and using different vaccine delivery systems. The RTS,S-SMC trial in which these data were collected was registered at clinicaltrials.gov: NCT03143218.
Sections du résumé
BACKGROUND
A recent trial of 5920 children in Burkina Faso and Mali showed that the combination of seasonal vaccination with the RTS,S/AS01
METHODS
In order to help optimise the timing of these two interventions, trial data were reanalysed to estimate the duration of protection against clinical malaria provided by RTS,S/AS01
RESULTS
The overall protective efficacy from RTS,S/AS01
CONCLUSIONS
The efficacy of both interventions was highest immediately post-administration. Understanding differences between these interventions in their peak efficacy and how rapidly efficacy declines over time will help to optimise the scheduling of SMC, malaria vaccination and the combination in areas of seasonal transmission with differing epidemiology, and using different vaccine delivery systems.
TRIAL REGISTRATION
The RTS,S-SMC trial in which these data were collected was registered at clinicaltrials.gov: NCT03143218.
Identifiants
pubmed: 36203149
doi: 10.1186/s12916-022-02536-5
pii: 10.1186/s12916-022-02536-5
pmc: PMC9540742
doi:
Substances chimiques
Antibodies, Protozoan
0
Malaria Vaccines
0
Banques de données
ClinicalTrials.gov
['NCT03143218']
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
352Subventions
Organisme : Medical Research Council
ID : MR/P006876/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R010161/1
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Informations de copyright
© 2022. The Author(s).
Références
PLoS One. 2008 May 21;3(5):e2227
pubmed: 18493597
Malar J. 2008 Oct 01;7:198
pubmed: 18828899
Lancet. 2021 May 15;397(10287):1809-1818
pubmed: 33964223
Am J Epidemiol. 1998 May 15;147(10):948-59
pubmed: 9596473
Malar J. 2017 May 2;16(1):182
pubmed: 28464937
Vaccine. 2020 Jul 6;38(32):4964-4969
pubmed: 32536547
Malar J. 2022 Feb 8;21(1):39
pubmed: 35135546
Cochrane Database Syst Rev. 2012 Feb 15;(2):CD003756
pubmed: 22336792
Malar J. 2011 Aug 04;10:223
pubmed: 21816032
PLoS Med. 2011 Feb 01;8(2):e1000407
pubmed: 21304923
PLoS One. 2008 Jan 23;3(1):e1471
pubmed: 18213379
Lancet. 2020 Dec 5;396(10265):1829-1840
pubmed: 33278936
PLoS Med. 2020 Aug 21;17(8):e1003214
pubmed: 32822362
Lancet. 2006 Feb 25;367(9511):659-67
pubmed: 16503464
PLoS Med. 2011 Feb 01;8(2):e1000408
pubmed: 21304925
BMJ Open. 2020 Sep 15;10(9):e035433
pubmed: 32933955
Clin Infect Dis. 2022 Sep 10;75(4):613-622
pubmed: 34894221
N Engl J Med. 2021 Sep 9;385(11):1005-1017
pubmed: 34432975
PLoS Med. 2021 Sep 8;18(9):e1003727
pubmed: 34495978
BMC Med Res Methodol. 2017 Apr 21;17(1):72
pubmed: 28431516
Lancet. 2015 Jul 4;386(9988):31-45
pubmed: 25913272